CNM-Au8 ( DrugBank: - )
2 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 2 | Amyotrophic lateral sclerosis | 6 |
| 13 | Multiple sclerosis/Neuromyelitis optica | 2 |
2. Amyotrophic lateral sclerosis
Clinical trials : 645 / Drugs : 589 - (DrugBank : 163) / Drug target genes : 150 - Drug target pathways : 225
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05281484 (ClinicalTrials.gov) | August 31, 2022 | 7/3/2022 | Intermediate Expanded Access Protocol (EAP) CNMAu8.EAP02 | A Second Intermediate Expanded Access Protocol for Amyotrophic Lateral Sclerosis With CNM-Au8 | Amyotrophic Lateral Sclerosis | Drug: CNM-Au8 | Clene Nanomedicine | NULL | Available | 18 Years | N/A | All | United States | ||
| 2 | NCT05299658 (ClinicalTrials.gov) | November 13, 2021 | 8/3/2022 | An Open-Label Extension for the Phase 2 Study in Early Symptomatic Amyotrophic Lateral Sclerosis Patients on Stable Background Therapy to Assess Bioenergetic Catalysis With CNM-Au8 to Slow Disease Progression in ALS | An Open-Label Extension for the Phase 2, Randomised, Double-Blind, Placebo-Controlled Study in Early Symptomatic Amyotrophic Lateral Sclerosis Patients on Stable Background Therapy to Assess Bioenergetic Catalysis With CNM-Au8 to Slow Disease Progression in ALS | Amyotrophic Lateral Sclerosis | Drug: CNMAu8 | Clene Nanomedicine | NULL | Active, not recruiting | 30 Years | 80 Years | All | 40 | Phase 2 | Australia |
| 3 | NCT03843710 (ClinicalTrials.gov) | April 30, 2021 | 14/2/2019 | 31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Amyotrophic Lateral Sclerosis (REPAIR-ALS) | A Phase 2, Pilot Open Label, Sequential Group, Investigator Blinded Study of Magnetic Resonance Spectroscopy (31P-MRS) to Assess the Effects of CNM-Au8 for the Bioenergetic Improvement of Impaired Neuronal Redox State in Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | Drug: Gold Nanocrystals | Clene Nanomedicine | University of Texas Southwestern Medical Center | Not yet recruiting | 35 Years | 75 Years | All | 24 | Phase 2 | United States |
| 4 | NCT04297683 (ClinicalTrials.gov) | July 14, 2020 | 3/3/2020 | HEALEY ALS Platform Trial - Master Protocol | HEALEY ALS Platform Trial | Amyotrophic Lateral Sclerosis | Drug: Zilucoplan;Drug: Verdiperstat;Drug: CNM-Au8;Drug: Pridopidine;Drug: SLS-005 Trehalose | Merit E. Cudkowicz, MD | Massachusetts General Hospital | Recruiting | 18 Years | N/A | All | 800 | Phase 2/Phase 3 | United States |
| 5 | NCT04098406 (ClinicalTrials.gov) | December 19, 2019 | 19/9/2019 | Therapeutic Nanocatalysis to Slow Disease Progression of Amyotrophic Lateral Sclerosis (ALS) | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study in Early Symptomatic Amyotrophic Lateral Sclerosis Patients on Stable Background Therapy to Assess Bioenergetic Catalysis With CNM-Au8 to Slow Disease Progression in ALS. | Amyotrophic Lateral Sclerosis | Drug: CNM-Au8;Drug: Placebo | Clene Nanomedicine | Clene Australia Pty Ltd | Completed | 30 Years | 80 Years | All | 45 | Phase 2 | Australia |
| 6 | NCT04081714 (ClinicalTrials.gov) | August 31, 2019 | 5/9/2019 | Intermediate Expanded Access Protocol for ALS | An Intermediate Expanded Access Protocol for Amyotrophic Lateral Sclerosis With CNM-Au8 | Amyotrophic Lateral Sclerosis | Drug: CNM-Au8 | Clene Nanomedicine | Massachusetts General Hospital | Available | 18 Years | N/A | All | United States |
13. Multiple sclerosis/Neuromyelitis optica
Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04626921 (ClinicalTrials.gov) | October 22, 2020 | 30/10/2020 | A Multi-Center, Open-Label Long-Term Extension Study of CNM-Au8 In Patients With Stable Relapsing Multiple Sclerosis | VISIONARY-MS LTE: A Multi-Center, Open-Label Long-Term Extension Study Assessing the Safety, Efficacy, Tolerability, and Pharmacokinetics of CNM-Au8 In Patients With Stable Relapsing Multiple Sclerosis | Relapsing Multiple Sclerosis | Drug: CNM-Au8 | Clene Nanomedicine | George Clinical | Active, not recruiting | 18 Years | 55 Years | All | 150 | Phase 2/Phase 3 | Australia;Canada;United States |
| 2 | NCT03993171 (ClinicalTrials.gov) | December 19, 2019 | 31/5/2019 | 31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Multiple Sclerosis. | A Phase 2, Open-Label, Sequential Group, Investigator Blinded Study of Magnetic Resonance Spectroscopy (31P-MRS) to Assess the Effects of CNM-Au8 for the Bioenergetic Improvement of Impaired Neuronal Redox State in Multiple Sclerosis. | Relapsing Remitting Multiple Sclerosis | Drug: gold nanocrystals | Clene Nanomedicine | University of Texas Southwestern Medical Center | Recruiting | 18 Years | 55 Years | All | 30 | Phase 2 | United States |